
Experts predict a bad flu season in the US in 2022, noting children and pregnant women in their third trimester are recommended to be the first in line for flu vaccination.

Experts predict a bad flu season in the US in 2022, noting children and pregnant women in their third trimester are recommended to be the first in line for flu vaccination.

Campho-Phenique is an antiseptic liquid indicated for the treatment of insect bites, minor skin irritations, and minor burns.

Humate-P is indicated for the treatment of adult patients with classical hemophilia (hemophilia A) and von Willebrand disease (VWD).

The company-sponsored phase 1/2 study evaluates a cryopreserved, readily available formulation for the treatment of follicular and diffuse large B cell lymphomas.

Pharmacists can help familiarize young patients with the vaccinations appropriate for pediatric use.

As treatments improve and prostate cancer potentially becomes more of a chronic illness, pharmacists have a chance to shine.

Treatment with biologic disease-modifying antirheumatic drugs associated with a higher overall risk, incidence, and recurrence of herpes zoster for patients with rheumatoid arthritis.

Study finds link between higher insulin doses and the risk of developing cancer in patients with type 1 diabetes.

New research links some beta-blockers and antiplatelet medications with a higher risk of experiencing a heart attack in hot weather.

Children may have suboptimal long-term brain development if their mother smokes tobacco consistently during pregnancy.

The FDA approval of fam-trastuzumab deruxtecan-nxki (Enhertu) to treat HER2 mutant non-small cell lung cancer was based on results from the DESTINY-Lung02 phase 2 trial.

Meropenem and vaborbactam is indicated for the treatment of complicated urinary tract infections for patients aged 18 years and older.

Baloxavir marboxil is the first and only single-dose oral medicine to treat influenza in children, a population who play a significant role as transmitters of influenza in the country.

Hearing and vision may not be considered hierarchically superior senses anymore, as a new study sheds light on the importance of taste and smell for quality of life.

Organizational determinants can play an important role in whether or not MTM programs are successful.

Xenia Tigno, PhD, and Reshma Jagsi, MD, DPhil, discuss how professional and societal pressures around the legitimacy of maternal leave versus paternal leave can impact the trajectory of women’s careers in medical research.

Lyme disease has reportedly spread geographically and increased in rural and urban populations during the past 15 years.

Health care providers’ recommendations will make a difference, results of a new poll from the University of Michigan show.

Topline results from the KarMMa-3 trial show that idecabtagene vicleucel significantly improves progression-free survival vs standard regimens.

Researchers studying the gut microbiome found that fiber supplements of any kind could improve gut health.

New study shows that race does not influence outcomes from immunotherapy for aggressive triple-negative breast cancer.

The Prescription Information Modernization Act seeks to modernize health care with up-to-date digital prescribing information to pharmacists.

A daily serving of meat can increase the risk of cardiovascular disease by 22% and our own gut microbes may contribute to this risk.

Lebrikizumab is a novel monoclonal antibody that binds with high affinity to the IL-13 protein to prevent the interaction between IL-13Rα1 and IL-4Rα, which blocks downstream signal activation along the IL-13 pathway.

A recent study suggests that homologous and heterologous vaccines protect against the Omicron variant of COVID-19, but the heterologous appears more durable.

Tuberculosis affects millions of people worldwide, but the only known vaccine may only protect children who are 5 years of age or younger.

Approximately 6000 participants aged 5 years and older at 50 sites in different countries are set to received 3 doses of VLA 15 µg or the saline placebo, followed by a booster.

The interim analysis of the TROPION-Lung02 trial demonstrate an overall response rate of 37% in individuals who were treated with datopotamab deruxtecan and pembrolizumab.

There are several key areas of risk that infusion practices are likely to face at some point, and proactively preparing for these events can help ensure a positive outcome.